Posts by: Janet Stewart, MSc

Janet Stewart, MSc

Janet Stewart is a life sciences writer and editor, who completed both PhD course work and oral examinations in the Department of Microbiology and Immunology at McGill University, and holds an M.Sc. in Virology and Immunology.

September 15, 2017September 15, 2017

Imfinzi Reduces Risk of Disease Progression in Advanced NSCLC Patients, PACIFIC Trial Shows

News

Imfinzi (durvalumab) increased the time to disease progression or death in patients with advanced, non-small cell lung cancer (NSCLC) who had not progressed following standard care with platinum-based concurrent chemoradiotherapy, ... Read more

August 21, 2017August 21, 2017

American Society of Clinical Oncology Updates Guidelines for Treatment of Advanced Non-Small Cell Lung Cancer

News

The American Society of Clinical Oncology (ASCO) recently updated its clinical guidelines for advanced non-small cell lung cancer (NSCLC) so that oncologists can select the most appropriate treatment for patients. Treatments for ... Read more

July 21, 2017July 21, 2017

Opdivo, Yervoy, and Keytruda May Induce Rare Adverse Reactions Affecting the Eye, FDA Says

News

The U.S. Food and Drug Administration (FDA) is considering adding the risk of eye toxicities that could cause vision loss and retinal detachment on the labels of Bristol-Myers Squibb’s Opdivo (nivolumab) ... Read more

July 18, 2017July 18, 2017

Celgene Working with BeiGene to Develop Its PD-1 Inhibitor, BGB-A317, to Treat Solid Tumors

News

Celgene Corporation has entered a strategic collaboration with BeiGene to develop and commercialize its PD-1 inhibitor BGB-A317, an immunotherapy primarily aimed at treating solid tumors, in the U.S., Europe, Japan and much of the world, ... Read more

June 9, 2017

Phase 1 Trial Results Show JTX-2011 was Well-tolerated in Advanced Solid Tumors

News

Jounce Therapeutics’ JTX-2011 was well-tolerated by patients with advanced solid tumors in the Phase 1/2 ICONIC clinical trial (NCT02904226), alone or in combination with Opdivo (nivolumab), supporting advancement of the ... Read more

May 3, 2017May 3, 2017

FDA Approves AstraZeneca’s Imfinzi for Previously Treated Advanced Bladder Cancer Patients

News

The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Imfinzi (durvalumab) to treat locally advanced or metastatic urothelial carcinoma, the most common type of bladder cancer. The approval, announced ... Read more

March 15, 2017

T-cells Need Extra Boost After Activation by Immune Checkpoint Inhibitors, Study Shows

News

Drugs used to treat some cancers still may need an extra boost to be effective, and a recent study found that stimulating the CD28 receptor might be the answer. Researchers found that certain ... Read more